» Articles » PMID: 36430277

Serum Immunoglobulin G Is a Marker of Hidradenitis Suppurativa Disease Severity

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Nov 26
PMID 36430277
Authors
Affiliations
Soon will be listed here.
Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory condition of the skin that is brought about by autoinflammation and hyperkeratosis at the pilosebaceous unit. The clinical severity of HS can be measured using static (Hurley Severity Scoring (HSS)) and/or dynamic (International HS Severity Scoring System (IHS4)) severity scoring instruments. However, few clinically available serological parameters have been found to correlate with disease severity. In this study, we sought to investigate the role of serum immunoglobulin (Ig) G, M and A levels as biomarkers of disease severity and to compare them with other, more conventional inflammatory indices, such as the erythrocyte sedimentation rate, C-reactive protein, the neutrophil-lymphocyte ratio, the platelet-lymphocyte ratio and the systemic immune-inflammation index. In this cross-sectional study, patients were recruited from the only dermatology referral centre in Malta, Europe, and subjected to clinical examination and the assessment of inflammatory and immunologic parameters. Serum IgG, M and A levels were assessed using the Atellica NEPH 630 System (SIEMENS-Healthineers AF, Erlangen, Germany) nephelometric analyser. Serum IgG, M and A levels correlate with both dynamic and static HS severity scoring systems. Serum IgG behaves as a marker of severe HS disease as categorised by HSS and the IHS4. Our findings suggest that the serum IgG level can be used in the clinical setting as a biomarker of disease severity and, therefore, as an adjunct to clinical severity scoring.

Citing Articles

Hypergammaglobulinemia in Hidradenitis Suppurativa Patients: A New Emerging Association.

Martora F, Battista T, Giordano A, Potestio L, Megna M Clin Cosmet Investig Dermatol. 2025; 18():1-5.

PMID: 39802669 PMC: 11724707. DOI: 10.2147/CCID.S503199.


IgG4 serologic elevation in a patient with severe hidradenitis suppurativa: a case report and review of the literature.

Gauger A, Fritz M, Burgin C Front Med (Lausanne). 2024; 11:1471226.

PMID: 39464270 PMC: 11502415. DOI: 10.3389/fmed.2024.1471226.


Hidradenitis Suppurativa: An Interdisciplinary Problem in Dermatology, Gynecology, and Surgery-Pathogenesis, Comorbidities, and Current Treatments.

Nowak-Liduk A, Kitala D, Ochala-Gierek G, Labus W, Bergler-Czop B, Pietrauszka K Life (Basel). 2023; 13(9).

PMID: 37763299 PMC: 10532726. DOI: 10.3390/life13091895.


A Retrospective Study of Clinical and Immunological Features of a Pediatric Population with Talaromyces marneffei Infection.

Chen H, Yan M, He H, Zhang L, Zeng H, Wang Y Mycopathologia. 2023; 188(3):221-230.

PMID: 37012558 PMC: 10069724. DOI: 10.1007/s11046-023-00724-2.

References
1.
Altman S, Criswell S . Dynamic Leukocyte Populations Are Associated With Early- and Late-stage Lesions in Hidradenitis Suppurativa. J Histochem Cytochem. 2020; 69(3):191-201. PMC: 7905492. DOI: 10.1369/0022155420978535. View

2.
Thorlacius L, Garg A, Riis P, Nielsen S, Bettoli V, Ingram J . Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol. 2019; 181(3):483-491. DOI: 10.1111/bjd.17716. View

3.
Gudjonsson J, Tsoi L, Ma F, Billi A, van Straalen K, Vossen A . Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight. 2020; 5(19). PMC: 7566715. DOI: 10.1172/jci.insight.139930. View

4.
Kromann C, Ibler K, Kristiansen V, Jemec G . The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol. 2014; 94(5):553-7. DOI: 10.2340/00015555-1800. View

5.
Assan F, Gottlieb J, Tubach F, Lebbah S, Guigue N, Hickman G . Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. J Allergy Clin Immunol. 2020; 146(2):452-455.e5. DOI: 10.1016/j.jaci.2020.01.045. View